Want to see DE:SBS full AI Analyst Report?
STRATEC Biomedical (SBS) Ratios
STRATEC Biomedical Ratios
DE:SBS's free cash flow for Q2 2026 was $7.04M. For the 2026 fiscal year, DE:SBS's free cash flow was decreased by $-1.19M and operating cash flow was $8.22M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.97 | 2.47 | 2.57 | 3.51 | 4.12 |
| Quick Ratio | 1.86 | 1.17 | 1.09 | 1.56 | 2.17 |
| Cash Ratio | 0.43 | 0.52 | 0.35 | 0.38 | 1.03 |
| Solvency Ratio | 0.09 | 0.18 | 0.14 | 0.27 | 0.36 |
| Operating Cash Flow Ratio | -0.01 | 0.54 | 0.20 | 0.17 | 1.39 |
| Short-Term Operating Cash Flow Coverage | -0.02 | 1.17 | 0.44 | 2.09 | 13.47 |
| Net Current Asset Value | $ 7.34M | $ 20.98M | $ 14.72M | $ 39.07M | $ 25.25M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.30 | 0.29 | 0.30 | 0.22 | 0.23 |
| Debt-to-Equity Ratio | 0.56 | 0.54 | 0.61 | 0.39 | 0.41 |
| Debt-to-Capital Ratio | 0.36 | 0.35 | 0.38 | 0.28 | 0.29 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.23 | 0.26 | 0.23 | 0.26 |
| Financial Leverage Ratio | 1.87 | 1.84 | 2.00 | 1.77 | 1.79 |
| Debt Service Coverage Ratio | 0.88 | 0.87 | 0.77 | 7.41 | 9.74 |
| Interest Coverage Ratio | 2.13 | 4.89 | 7.21 | 27.81 | 35.25 |
| Debt to Market Cap | 0.44 | 0.32 | 0.23 | 0.07 | 0.05 |
| Interest Debt Per Share | 11.20 | 11.21 | 11.95 | 7.31 | 7.16 |
| Net Debt to EBITDA | 4.01 | 1.76 | 2.50 | 1.12 | 0.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 25.60% | 29.65% | 25.21% | 28.94% | 30.53% |
| EBIT Margin | 3.43% | 10.83% | 9.44% | 14.78% | 16.80% |
| EBITDA Margin | 10.84% | 18.38% | 15.96% | 20.95% | 23.15% |
| Operating Profit Margin | 3.43% | 10.94% | 10.40% | 15.29% | 17.27% |
| Pretax Profit Margin | 1.93% | 8.54% | 7.97% | 14.23% | 16.30% |
| Net Profit Margin | -0.10% | 6.22% | 5.68% | 10.64% | 13.91% |
| Continuous Operations Profit Margin | -0.10% | 6.22% | 5.68% | 10.64% | 13.91% |
| Net Income Per EBT | -4.99% | 72.80% | 71.34% | 74.76% | 85.32% |
| EBT Per EBIT | 56.40% | 78.09% | 76.61% | 93.07% | 94.35% |
| Return on Assets (ROA) | -0.05% | 3.60% | 3.29% | 7.35% | 10.84% |
| Return on Equity (ROE) | -0.10% | 6.61% | 6.59% | 12.98% | 19.42% |
| Return on Capital Employed (ROCE) | 2.21% | 7.95% | 7.60% | 12.45% | 15.37% |
| Return on Invested Capital (ROIC) | -0.10% | 5.13% | 4.64% | 9.12% | 12.85% |
| Return on Tangible Assets | -0.07% | 4.84% | 4.35% | 9.45% | 14.31% |
| Earnings Yield | -0.09% | 4.42% | 2.78% | 2.97% | 2.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.43 | 5.97 | 3.72 | 4.72 | 6.92 |
| Payables Turnover | 14.77 | 9.82 | 9.43 | 17.96 | 17.51 |
| Inventory Turnover | 1.65 | 1.54 | 1.42 | 1.66 | 2.25 |
| Fixed Asset Turnover | 3.27 | 3.21 | 3.22 | 3.71 | 4.26 |
| Asset Turnover | 0.57 | 0.58 | 0.58 | 0.69 | 0.78 |
| Working Capital Turnover Ratio | 1.71 | 1.81 | 1.79 | 1.87 | 2.19 |
| Cash Conversion Cycle | 302.92 | 260.91 | 316.72 | 277.01 | 194.19 |
| Days of Sales Outstanding | 106.29 | 61.18 | 98.04 | 77.31 | 52.72 |
| Days of Inventory Outstanding | 221.35 | 236.89 | 257.39 | 220.03 | 162.31 |
| Days of Payables Outstanding | 24.71 | 37.15 | 38.72 | 20.32 | 20.85 |
| Operating Cycle | 327.63 | 298.06 | 355.44 | 297.34 | 215.03 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.04 | 4.01 | 1.60 | 0.85 | 5.24 |
| Free Cash Flow Per Share | -0.80 | 2.51 | 0.16 | -0.72 | 3.57 |
| Dividend Paid and CapEx Coverage Ratio | -0.03 | 1.96 | 0.66 | 0.34 | 2.04 |
| Capital Expenditure Coverage Ratio | -0.05 | 2.68 | 1.11 | 0.54 | 3.14 |
| Operating Cash Flow Coverage Ratio | -0.00 | 0.37 | 0.14 | 0.12 | 0.74 |
| Operating Cash Flow to Sales Ratio | -0.00 | 0.19 | 0.07 | 0.04 | 0.22 |
| Free Cash Flow Yield | -3.56% | 8.43% | 0.36% | -0.89% | 2.59% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1128.14 | 22.58 | 36.03 | 33.67 | 41.77 |
| Price-to-Sales (P/S) Ratio | 1.09 | 1.41 | 2.05 | 3.58 | 5.81 |
| Price-to-Book (P/B) Ratio | 1.15 | 1.49 | 2.37 | 4.37 | 8.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.10 | 11.87 | 276.71 | -112.57 | 38.60 |
| Price-to-Operating Cash Flow Ratio | -630.26 | 7.44 | 28.50 | 95.72 | 26.29 |
| Price-to-Earnings Growth (PEG) Ratio | 11.11 | 4.74 | -0.75 | -1.25 | 1.15 |
| Enterprise Value Multiple | 14.05 | 9.41 | 15.33 | 18.22 | 25.66 |
| Enterprise Value | 381.98M | 445.62M | 661.54M | 1.05B | 1.71B |
| EV to EBITDA | 14.05 | 9.41 | 15.33 | 18.22 | 25.66 |
| EV to Sales | 1.52 | 1.73 | 2.45 | 3.82 | 5.94 |
| EV to Free Cash Flow | -39.33 | 14.60 | 330.61 | -119.95 | 39.48 |
| EV to Operating Cash Flow | -882.16 | 9.15 | 34.06 | 101.99 | 26.89 |
| Tangible Book Value Per Share | 10.64 | 10.58 | 9.87 | 11.29 | 9.61 |
| Shareholders’ Equity Per Share | 19.52 | 19.95 | 19.19 | 18.56 | 16.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 1.05 | 0.27 | 0.29 | 0.25 | 0.15 |
| Revenue Per Share | 20.64 | 21.19 | 22.25 | 22.64 | 23.73 |
| Net Income Per Share | -0.02 | 1.32 | 1.26 | 2.41 | 3.30 |
| Tax Burden | -0.05 | 0.73 | 0.71 | 0.75 | 0.85 |
| Interest Burden | 0.56 | 0.79 | 0.84 | 0.96 | 0.97 |
| Research & Development to Revenue | 0.07 | 0.05 | 0.03 | 0.03 | 0.03 |
| SG&A to Revenue | 0.15 | 0.14 | 0.07 | 0.07 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Income Quality | 1.79 | 3.04 | 1.49 | 0.35 | 1.59 |
Currency in EUR
